Literature DB >> 24100396

Proteinuria: does vitamin D treatment improve outcomes in CKD?

Suetonia C Palmer1, Giovanni F M Strippoli.   

Abstract

In a meta-analysis of randomized trials, de Borst and colleagues report that vitamin D therapy reduces proteinuria and might also slow the progression of chronic kidney disease. In light of the limited options for renoprotective therapy, we evaluate whether this evidence for vitamin D treatment justifies a large, definitive trial.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24100396     DOI： 10.1038/nrneph.2013.209

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

Review 1.  Surrogate end points for clinical trials of kidney disease progression.

Authors:  Lesley A Stevens; Tom Greene; Andrew S Levey
Journal:  Clin J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 8.237

2.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

Review 3.  Antihypertensive agents for preventing diabetic kidney disease.

Authors:  Jicheng Lv; Vlado Perkovic; Celine V Foote; Maria E Craig; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Authors:  P Ruggenenti; A Perna; G Gherardi; G Garini; C Zoccali; M Salvadori; F Scolari; F P Schena; G Remuzzi
Journal:  Lancet       Date:  1999-07-31       Impact factor: 79.321

5.  Relation between kidney function, proteinuria, and adverse outcomes.

Authors:  Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli
Journal:  JAMA       Date:  2010-02-03       Impact factor: 56.272

6.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

7.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

Review 8.  Active vitamin D treatment for reduction of residual proteinuria: a systematic review.

Authors:  Martin H de Borst; Reza Hajhosseiny; Hector Tamez; Julia Wenger; Ravi Thadhani; David J A Goldsmith
Journal:  J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 10.121

9.  Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats.

Authors:  Masahide Mizobuchi; Jeremiah Morrissey; Jane L Finch; Daniel R Martin; Helen Liapis; Tadao Akizawa; Eduardo Slatopolsky
Journal:  J Am Soc Nephrol       Date:  2007-05-18       Impact factor: 10.121

Review 10.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Authors:  Pawana Sharma; Rachel C Blackburn; Claire L Parke; Keith McCullough; Angharad Marks; Corri Black
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05
  10 in total
  1 in total

1.  The use of vitamin D analogs is independently associated with the favorable renal prognosis in chronic kidney disease stages 4-5: the CKD-ROUTE study.

Authors:  Yohei Arai; Eiichiro Kanda; Soichiro Iimori; Shotaro Naito; Yumi Noda; Tomoki Kawasaki; Hidehiko Sato; Ryoichi Ando; Sei Sasaki; Eisei Sohara; Tomokazu Okado; Tatemitsu Rai; Shinichi Uchida
Journal:  Clin Exp Nephrol       Date:  2016-06-25       Impact factor: 2.801
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.